ACTR-26. TOXICITY AND EFFICACY OF LOMUSTINE PLUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS

BACKGROUND: Bevacizumab combined with chemotherapy has shown high response rates in recurrent glioblastoma patients and responding patients have improved survival and quality of life. The Danish treatment recommendations for recurrent glioblastoma patients were recently changed by replacing irinotec...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Jakobsen, Jan Nyrop, Urup, Thomas, Grunnet, Kirsten, Christensen, Ib Jarle, Villingshøj, Mette, Poulsen, Hans Skovgaard
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2017
Gaiak:
Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692348/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.021
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak